According to the American Parkinson Disease Association, Parkinson’s disease (PD) is a type of movement disorder that can affect the ability to perform common, daily activities. It is a chronic and progressive disease, meaning that the symptoms become worse over time. It is characterized by its most common of motor symptoms—tremors (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia)—but also manifests in non-motor symptoms including sleep problems, constipation, anxiety, depression, and fatigue, among others.
There are an estimated 1 million people in the U.S. living with Parkinson’s disease and more than 10 million people worldwide. Most people who develop the symptoms of Parkinson’s disease do so sometime after the age of 50, but Parkinson’s disease can affect younger persons as well. Approximately 10% of Parkinson’s diagnoses occur before age 50—these diagnoses are called Early Onset (or Young Onset) Parkinson’s disease.
The following case study suggest “that HBO therapy might be a potential therapeutic modality in treating patients suffering from PD without causing untoward side effects such as dyskinesia observed in long-term Sinemet therapy. In conclusion, we suggest that HBO therapy might be neuroprotective in nature to the nigrostriatal neurons by acting as an antiapoptotic process. This could stabilize neuronal function, thereby potentially decreasing the progression of the neurodegeneration observed in Parkinson’s Disease.”